{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:37:49Z","timestamp":1789231069236,"version":"build-2803163510"},"reference-count":66,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RC-2023-2778909"],"award-info":[{"award-number":["RC-2023-2778909"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>This systematic review examines the available clinical data on CD34+ cell mobilization, collection, and engraftment in multiple myeloma patients treated with the anti-CD38 monoclonal antibodies daratumumab and isatuximab in clinical trials and in real life. Twenty-six clinical reports were published between 2019 and February 2024. Most studies documented lower circulating CD34+ cells after mobilization compared to controls, leading to higher plerixafor requirements. Although collection yields were significantly lower in approximately half of the studies, the collection target was achieved in similar proportions of daratumumab- and isatuximab-treated and nontreated patients, and access to autologous stem cell transplant (ASCT) was comparable. This could be explained by the retained efficacy of plerixafor in anti-CD38 monoclonal antibody-treated patients, while no chemotherapy-based or sparing mobilization protocol proved superior. Half of the studies reported slower hematopoietic reconstitution after ASCT in daratumumab- and isatuximab-treated patients, without an excess of infectious complications. While no direct effect on stem cells was observed in vitro, emerging evidence suggests possible dysregulation of CD34+ cell adhesion after daratumumab treatment. Overall, anti-CD38 monoclonal antibodies appear to interfere with CD34+ cell mobilization, without consistently leading to significant clinical consequences. Further research is needed to elucidate the underlying mechanisms and define optimal mobilization strategies in this patient population.<\/jats:p>","DOI":"10.3390\/ph17070944","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:17:32Z","timestamp":1721067452000},"page":"944","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients\u2014A Systematic Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Flavia","family":"Bigi","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Manzato","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-8230","authenticated-orcid":false,"given":"Simona","family":"Barbato","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Talarico","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Puppi","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Masci","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Sacchetti","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Restuccia","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Iezza","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-9266","authenticated-orcid":false,"given":"Ilaria","family":"Rizzello","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-5691","authenticated-orcid":false,"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-0129","authenticated-orcid":false,"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pantani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9576-5118","authenticated-orcid":false,"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-3227","authenticated-orcid":false,"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): Final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Pieter","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"JCO"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"ref_11","first-page":"309","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"17","author":"Dimopoulos","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","unstructured":"(2021, November 30). NCCN Guidelines Versione 1.2022 Mieloma multiplo NCCN Guidelines\u00ae e Questa Illustrazione non Possono Essere Riprodotte in Nessuna Forma Senza L\u2019espresso Permesso Scritto di NCCN. NCCN Guidelines Index Indice Discussione Divulgazioni del Gruppo di Esperti. Available online: https:\/\/www.nccn.org\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","article-title":"A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients","volume":"27","author":"Fitoussi","year":"2001","journal-title":"Bone Marrow Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","article-title":"Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma","volume":"31","author":"Jantunen","year":"2003","journal-title":"Bone Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","article-title":"Advances in stem cell mobilization","volume":"28","author":"Hopman","year":"2014","journal-title":"Blood Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41409-021-01251-8","article-title":"Chemotherapy-based versus chemotherapy-free stem cell mobilization (\u00b1plerixafor) in multiple myeloma patients: An Italian cost-effectiveness analysis","volume":"56","author":"Lazzaro","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jha2.702","article-title":"A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction","volume":"4","author":"Chandler","year":"2023","journal-title":"EJHaem"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bigi, F., Tacchetti, P., Giorgi, A., Mazzocchetti, G., Solli, V., Barbato, S., Sinigaglia, B., Campanini, E., Favero, E., and Talarico, M. (2024). Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cells in Multiple Myeloma patients. Front. Hematol., 3.","DOI":"10.3389\/frhem.2024.1386973"},{"key":"ref_19","unstructured":"Zappaterra, A., Civettini, I., Cafro, A.M., Pezzetti, L., Pierini, S., Anghilieri, M., Bellio, L., Bertazzoni, P., Grillo, G., and Minga, P. (Blood Transfus., 2024). Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients: CD38 antibody impacts on HSC mobilization and clonogenicity, Blood Transfus., online ahead of print."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjh.19141","article-title":"Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy","volume":"204","author":"Venglar","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142115","article-title":"Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant","volume":"136","author":"Manjappa","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-018-0119-4","article-title":"Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth","volume":"7","author":"Ma","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab and lenalidomide\u2013containing quadruplet induction therapy in newly diagnosed multiple myeloma: Findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s12288-019-01135-4","article-title":"Poor Mobilisation after Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma","volume":"35","author":"Mishra","year":"2019","journal-title":"Indian. J. Hematol. Blood Transfus."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.14008","article-title":"Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody","volume":"111","author":"Seth","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12288-020-01273-0","article-title":"Peri-transplant Stem Cell Kinetics After Daratumumab-Based Induction in Patients with Multiple Myeloma: Response to Mishra et al","volume":"36","author":"Jain","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2022-160071","article-title":"Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara) | Elsevier Enhanced Reader","volume":"140","author":"Manisha","year":"2022","journal-title":"Blood"},{"key":"ref_29","first-page":"E8","article-title":"Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma","volume":"95","author":"Sidiqi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1182\/blood-2023-177624","article-title":"Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience","volume":"142","author":"Bourlon","year":"2023","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2023-185907","article-title":"Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis","volume":"142","author":"Cavallaro","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood-2022-169367","article-title":"Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma","volume":"140","author":"Jacob","year":"2022","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1182\/blood-2023-188780","article-title":"Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience","volume":"142","author":"Fazio","year":"2023","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3324\/haematol.2022.281610","article-title":"Impact of daratumumab based induction on stem cell collection parameters in Swedish myeloma patients","volume":"108","author":"Lemonakis","year":"2022","journal-title":"Haematol"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.3324\/haematol.2023.283452","article-title":"Higher cyclophosphamide dose grants optimal stem-cell collection after daratumumab-based induction in multiple myeloma","volume":"108","author":"Liberatore","year":"2023","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-140811","article-title":"Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use","volume":"136","author":"Luan","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"Terpos","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000529691","article-title":"Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma","volume":"50","author":"Sauer","year":"2023","journal-title":"Transfus. Med. Hemoth."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"340.e1","DOI":"10.1016\/j.jtct.2023.02.013","article-title":"Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab Based Induction Therapy\u2014A Real World Experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kauer, J., Freundt, E.P., Schmitt, A., Weinhold, N., Mai, E.K., M\u00fcller-Tidow, C., Goldschmidt, H., Raab, M.S., Kriegsmann, K., and Sauer, S. (2023). Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: A single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11507-9"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood-2023-181323","article-title":"Prior Daratumumab Exposure and It\u2019s Correlation to Parameters Related to Apheresis Prior to Hematopoietic Stem Cell Transplantation in Multiple Myeloma","volume":"142","author":"Unis","year":"2023","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1182\/blood-2023-180082","article-title":"Impact of Daratumumab on Hematopoietic Stem Cell Mobilization with G-CSF and on-Demand Plerixafor in Newly-Diagnosed Multiple Myeloma Patients","volume":"142","author":"Mina","year":"2023","journal-title":"Blood"},{"key":"ref_43","first-page":"S261","article-title":"Impact of daratumumab (DARA) administration during transplant-eligible newly diagnosed multiple myeloma (TE NDMM) induction on stem cell (SC) mobilization count and post-transplant engraftment","volume":"43","author":"Crusoe","year":"2021","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1182\/blood-2022-171098","article-title":"Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Oza","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor Mobilization of Hematopoietic Stem Cells\u2014Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s12325-018-0815-9","article-title":"Pharmacokinetics and Exposure\u2013Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma","volume":"35","author":"Xu","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: A position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2013.52","article-title":"Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies","volume":"48","author":"Awan","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21280","article-title":"Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF","volume":"28","author":"Chaudhary","year":"2013","journal-title":"J. Clin. Apher."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41409-020-0940-3","article-title":"Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma","volume":"55","author":"Nerich","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_54","unstructured":"Attolico, I., Strafella, V., Tarantini, F., and Carluccio, P. (2024, January 14\u201317). Impact of Dara-VTD induction therapy on hematopoietic stem cell collection and engraftment in Multiple Myeloma patients eligible for ASCT: Results of the real-life PRIMULA study [E-poster abstract]. Proceedings of the 50th Annual Meeting of the European Group for Blood and Marrow Transplantation, Glasgow, UK."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","article-title":"Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbmt.2019.11.024","article-title":"Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma","volume":"26","author":"Shah","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhu, C., Song, Z., Wang, A., Srinivasan, S., Yang, G., Greco, R., Theilhaber, J., Shehu, E., Wu, L., and Yang, Z.-Y. (2020). Isatuximab Acts through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01771"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/bloodadvances.2017014506","article-title":"Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells","volume":"2","author":"Mele","year":"2018","journal-title":"Blood Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2010.36","article-title":"CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells","volume":"24","author":"Vaisitti","year":"2010","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00520-013-1808-5","article-title":"Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma","volume":"21","author":"Bhutani","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/trf.14220","article-title":"Impact of lenalidomide-based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: A prospective multicenter study","volume":"57","author":"Partanen","year":"2017","journal-title":"Transfusion"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1046\/j.1365-2141.2001.02498.x","article-title":"Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone","volume":"112","author":"Desikan","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41409-021-01300-2","article-title":"The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft","volume":"56","author":"Rees","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/raon-2016-0028","article-title":"Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma","volume":"50","author":"Skerget","year":"2016","journal-title":"Radiol. Oncol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/944\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:16:54Z","timestamp":1760109414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/7\/944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":66,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ph17070944"],"URL":"https:\/\/doi.org\/10.3390\/ph17070944","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}